Study Year of publication Study
design 		Patients/
implants 		ADs Gender Follow-up
perioda 		Survival rate of implants Survival rate of
suprastructures 		Crestal
bone lossa 		PI Success rate
n/n M/F Months % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n suprastructures) 		mm % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n implants)
Mozzati et al. [5] 2021 RS 5/12 SLE 3/2 Mean: 58.5 100% (5/5)
100% (12/12) 		100% (5/5)
NR 		Mean: 0.49 0% (0/5)
0% (0/12) 		NR
Petsinis et al. [7] 2017 RS 3/14 SLEb 1/2 Mean: 50.3 100% (3/3)
100% (14/14) 		100% (3/3)
NR 		NR 0% (0/3)
0% (0/14) 		NR
Drew et al. [37] 2018 CR 1/15 SLEb 0/1 > 18 0% (0/1)
93.3% (14/15)
Early loss: 1
Late loss: 0 		100% (1/1)
100% (2/2) 		NR 0% (0/1)
0% (0/15) 		NR
Ergun et al. [40] 2010 CR 1/6 SLE+PA 0/1 24 100% (1/1)
100% (6/6) 		100% (1/1)
100% (5/5) 		NR NR NR
Li et al. [51] 2004 CR 1/5 SLE+MCTD 0/1 36 100% (1/1)
100% (5/5) 		100% (1/1)
NR 		NR NR NR
Chochlidakis
et al. [65] 		2016 CR 1/6 SLE+HT+sSS 0/1 14 100% (1/1)
100% (6/6) 		100% (1/1)
100% (2/2) 		NR NR NR
Overall
SLE - CR: 4
RS: 2 		12/58 - Ratio: 1/2 Mean: 47 91.7% (11/12)
98.3% (57/58)
Of these: 100% (1/1) early loss 		100% (12/12)
100% (9/9) 		Mean: 0.49 0% (0/9)
0% (0/41) 		NR
SLE
+ concomitant ADs 		- CR: 3 3/17 - Ratio: 0/3 Mean: 24.7 100% (3/3)
100% (17/17) 		100% (3/3)
100% (7/7) 		NR NR NR

a = weighted mean or median; b = remission at implant placement.
ADs = autoimmune diseases; CR = case report; HT = hypothyroidism; M/F = male/female; MCTD = mixed connective tissue disease; N = number; NR = not reported; PA = polyarthritis; PI = peri-implantitis; RS = retrospective study; sSS = secondary Sjögren's syndrome.